Exiqon A/S, a leading supplier of high-value gene expression analysis products today announces that it has signed an agreement to exclusively license a microRNA quantitative real-time PCR technology from Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co., Inc. (NYSE: MRK). The details of the financial terms of the license agreement are not disclosed.
